Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study

Table 1 Clinical characteristics of the discovery cohort

Clinical characteristics	Good outcome group	Poor outcome group	p value
n	203	196
Age (years)
Median	37	36	0.89
Range	25–40	18–41	0.89
Relapse (years)
Median	9.3	1.3	< 0.0001
Range	5.0–10.2	0.4–2.0	< 0.0001
BMI (kg/m²)
Mean	25.2	26.3	0.13*
SD	5.1	5.4	0.13*
Histology
Invasive ductal carcinoma	203	190
Invasive lobular carcinoma	0	0
Unknown	0	6
Grade 1	10	6
Grade 2	75	47
Grade 3	114	137
Unknown	4	6
Lymph node status
Negative	104	61	< 0.0001
Positive	95	127	< 0.0001
Undetermined	4	8
ER status
Positive	138	108	< 0.0001
Negative	43	88	< 0.0001
Unknown	22	0
PR status
Positive	87	75	0.43
Negative	79	86
Unknown	42	35
HER2 receptor status
Positive	53	82	0.77
Negative	59	92
Unknown	91	22
Triple-negative tumours	32	35
Resection margin
R0 resection	142	141
R1 resection	24	22
Unknown	37	33
Chemotherapy
FEC	69	71
ECMF	28	31
FEC + docetaxel	22	14
AC	16	16
EC + paclitaxel	15	12
EC + paclitaxel + gemcitabine	8	8
EC	8	6
Null	22	8
Other	15	30

A adriamycin, BI body mass index, C cyclophosphamide, E epirubicin, ER oestrogen receptor, F 5-fluorouracil, HER2 human epidermal growth factor receptor 2, M methotrexate, PR progesterone receptor, SD standard deviation
*Unpaired T-test between groups

ISSN: 1465-542X